Qulipta, a medication used to prevent migraine, is not associated with weight loss. In clinical trials, weight gain was a more frequently reported side effect than weight loss for Qulipta [1].
What side effects are patients asking about for Qulipta?
Patients often inquire about the potential side effects of Qulipta. Beyond weight changes, other reported side effects in clinical trials include fatigue, nausea, and upper respiratory tract infections. Less common side effects can include constipation, indigestion, and dizziness [1].
How does Qulipta work to prevent migraines?
Qulipta, with the active ingredient atogepant, is a calcitonin gene-related peptide (CGRP) receptor antagonist. It works by blocking the action of CGRP, a molecule that plays a role in migraine pain [1]. By inhibiting CGRP, Qulipta is thought to reduce the inflammation and vasodilation associated with migraine attacks [2].
When does Qulipta's patent protection expire?
Information regarding specific patent expiry dates for Qulipta is available through specialized patent tracking services. DrugPatentWatch.com provides detailed data on drug patents, including their expiration timelines [3].
Are there alternative treatments for migraine prevention?
Yes, several alternative treatments exist for migraine prevention, including other CGRP antagonists, beta-blockers, anticonvulsants, and antidepressants. Lifestyle modifications, such as identifying and avoiding triggers, managing stress, and maintaining regular sleep patterns, can also be part of a comprehensive migraine management plan.
Sources:
1. https://www.drugpatentwatch.com/p/qulipta-atogepant
2. https://www.drugpatentwatch.com/blog/what-is-calcitonin-gene-related-peptide-cgrp-and-how-do-cgrp-inhibitors-work
3. https://www.drugpatentwatch.com/